Clinical Trials · NCT03082885
The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Sun Yat-sen University
- Enrollment
- 120
- Start date
- Apr 2017
- Locations
- 1 site, China
- Primary endpoint
- The liver transplantation-free survival rate of 90 days